MYmAb Biologics Expands Global Reach Through Strategic Distributor Partnerships, Advancing Equity in Cancer Research
Strengthening its international footprint, MYmAb Biologics has entered strategic collaborations with two well-established global distributors: ABreal Biotech and 2BScientific. These partnerships mark a significant milestone in MYmAb Biologics’ growth, enabling broader access to its tissue microarray solutions across key research markets in Europe, North America, and beyond.
By working with ABreal Biotech and 2BScientific, MYmAb Biologics enhances its ability to deliver innovative, tailored tissue microarray solutions to researchers worldwide. Both distributors bring strong domain expertise, established networks, and proven logistics capabilities, ensuring that MYmAb Biologics’ TMAs are accessible, supported, and efficiently delivered to laboratories conducting cutting-edge biomedical and cancer research.
Central to MYmAb Biologics’ offering is ArrayZeal™, its proprietary tissue microarray platform designed to address a critical gap in global cancer research. ArrayZeal™ provides researchers with access to diverse cancer tissue samples sourced from underrepresented populations in Southeast Asia (SEA). By enabling studies that better reflect population diversity, ArrayZeal™ supports more inclusive data generation and promotes equity in global cancer research, biomarker discovery, and therapeutic development.
Through these distributor collaborations, MYmAb Biologics is well positioned to scale the impact of ArrayZeal™ and its broader tissue microarray portfolio, empowering researchers with ethically sourced, high-quality human tissues that improve the relevance and translational value of their findings.
To learn more about MYmAb Biologics tissue microarray solutions visit our product page.